Why the study?
To explore the data behind vernakalant and discuss how it can be introduced into clinical practice for pharmacological cardioversion of recent onset AF.
Does vernakalant improve restoration of sinus rhythm in patients with recent onset atrial fibrillation?
Does vernakalant improve restoration of sinus rhythm in patients with recent onset atrial fibrillation?
Vernakalant is an effective pharmacological option for cardioversion of recent onset AF that may facilitate early hospital discharge.
Supports vernakalant for early discharge in selected recent-onset AF; leaves open need for randomized confirmation.
Vernakalant is an antiarrhythmic drug licensed for the pharmacological cardioversion of recent onset AF. Randomised clinical trials, backed up by real-world experience, have confirmed its efficacy at restoring sinus rhythm. Vernakalant can be administered simply with a short time to action, facilitating early discharge from hospital in selected patients in place of electrical cardioversion. The authors explore the data behind vernakalant and discuss how it can be introduced into clinical practice.
No takes yet. Share an insight, caveat, or question.
Hall et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: